Skip to main content
Fig. 7 | BMC Medical Genomics

Fig. 7

From: Identification and validation of a novel predictive signature based on hepatocyte-specific genes in hepatocellular carcinoma by integrated analysis of single-cell and bulk RNA sequencing

Fig. 7

Analysis of the immune status and the immunotherapy effect according to the risk score. Immune function and immune cell expression levels between different risk groups were observed by the heatmap (A) and the boxplot (B). (C) Differences in the TIDE score between different risk groups. (D) Differences in the relevant immune checkpoint levels between different risk groups. (E) Differences in the immunotherapy sensitivity to the PD1 inhibitors, the CTLA-4 inhibitors, and their combination across distinct risk groups. * P < 0.05, ** P < 0.01, *** P < 0.001, ns: The difference is not significant

Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us